

December 4, 2023

SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director,  
President and Chief Executive Officer  
Takaaki Fukushima  
Vice President Corporate Officer and Chief Financial Officer  
TEL: +81-3-5472-1125

### Notice Regarding Adjustment of Exercise Price

SymBio Pharmaceuticals Limited (the “Company”) hereby announces that in conjunction with the issue of new shares through third-party allotment to EVO FUND, which was resolved at the Board of Directors’ meeting held on Friday, October 6, 2023, it will revise the exercise price of the 58th Share Acquisition Rights, as below.

#### 1. Adjustment of Exercise Price

| Name of stock acquisition rights                               | Exercise price after adjustment | Exercise price before adjustment |
|----------------------------------------------------------------|---------------------------------|----------------------------------|
| SymBio Pharmaceuticals Limited’s 58th Stock Acquisition Rights | ¥261                            | ¥316                             |

#### 2. Applicable Date

From Wednesday, December 20, 2023

#### 3. Reason for Adjustment

The exercise price will be adjusted because the payment amount for the issue of new shares through third-party allotment to EVO FUND (resolved at a Board of Directors’ meeting held on Friday, October 6, 2023) resolved on Monday, December 4, 2023, was lower than the exercise price effective as of the applicable commencement date stipulated in 10, Item (2), 1) of the Terms and Conditions for the Issuance of SymBio Pharmaceuticals Limited’s 58th Stock Acquisition rights.